Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina, Inc. (NASDAQ: ILMN) is at the forefront of genomic technology, providing innovative tools and services to analyze genetic material. With a primary focus on DNA sequencing and array-based technologies, Illumina serves a diverse range of markets including life sciences, oncology, reproductive health, and agriculture. Over 90% of its revenue stems from sequencing instruments, consumables, and services, with the remainder coming from microarrays used in genetic screening for consumer and agricultural applications. Illumina's technology enables high-throughput whole genome sequencing, which is essential for large-scale genomic studies, as well as lower throughput tools for specific applications such as viral and cancer tumor screening.
Recent advancements at Illumina include the upcoming release of their first quarter 2024 financial results, showcasing significant improvements in both gross and non-GAAP operating margins. The company's innovative solutions continue to drive sequencing activity globally, despite challenging economic conditions. Illumina's NovaSeq X Sequencing System exemplifies their cutting-edge research and development efforts, demonstrating the company's commitment to delivering superior technology for genomic analysis.
In the oncology domain, Illumina's Whole-Genome Sequencing (WGS) and Comprehensive Genomic Profiling (CGP) are setting new standards for cancer diagnostics and treatment. By collaborating with leading institutions and pharmaceutical companies, Illumina is enhancing the scientific understanding of cancer biology and developing advanced assays for Molecular Residual Disease (MRD) detection. These efforts are crucial in precision oncology, enabling early detection and personalized treatment strategies.
Illumina is also committed to expanding access to genomic testing. Through initiatives like The Future Is Bright and partnerships with educational institutions, the company is fostering the next generation of scientists. Their volunteer programs and educational outreach aim to increase genomic literacy and inspire students to pursue careers in STEM fields.
Furthermore, Illumina's ongoing collaboration with GRAIL, Inc., a wholly-owned subsidiary focused on early cancer detection, highlights the company's dedication to transformative healthcare solutions. Despite regulatory challenges, Illumina remains steadfast in its mission to unlock the power of the genome and improve human health.
Stay updated with Illumina's latest developments and financial performance by visiting their website and connecting on social media platforms like X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.
GRAIL, a healthcare company focused on early cancer detection, has partnered with Point32Health to pilot its Galleri multi-cancer early detection blood test. This initiative marks Point32Health as the first U.S. commercial health plan to collaborate with GRAIL on this innovative test. The pilot will begin with Point32Health employees and later expand to commercial members, aiming to gather real-world evidence on its effectiveness. Galleri can detect over 50 cancer types with a low false positive rate, potentially saving lives by enabling earlier treatment.
Illumina reported Q4 2021 revenue of $1,198 million, marking a 26% increase year-over-year. GAAP net income was $112 million or $0.71 per diluted share, down from $257 million or $1.75 the previous year. For fiscal 2021, total revenue reached $4,526 million, up 40% from $3,239 million in 2020. However, cash flow from operations fell to $545 million from $1,080 million in the prior year. The company expects consolidated revenue growth between 14% to 16% for 2022 and GAAP earnings per share of $3.04 to $3.24.
Illumina (NASDAQ: ILMN) announced its participation in two upcoming investor conferences. The SVB Leerink 2022 Global Healthcare Conference will feature a fireside chat on February 17, 2022, at 9:00 AM PT. The Citi 2022 Healthcare Conference will follow with another chat on February 24, 2022, at 9:30 AM PT. Both events will be accessible via live webcast through Illumina's website, with replays available for at least 30 days afterward. Illumina continues to lead in DNA sequencing technology, enhancing global health.
Illumina has formed a partnership with the Jean Perrin Center at Clermont-Ferrand University Hospital in France to evaluate comprehensive genomic profiling (CGP) in late-stage cancer patients. This collaboration will utilize data from the CELIA study to compare CGP effectiveness against standard care approaches, including small panel tests. The TruSight™ Oncology 500 assay will be employed to analyze genetic mutations in various cancer types, aiming to enhance precision oncology practices. The study seeks to solidify CGP's role in French healthcare and ultimately improve patient outcomes.
Illumina (NASDAQ: ILMN) has partnered with the National Cancer Center Japan for a research project focused on nasopharyngeal carcinoma, particularly prevalent in Asia. This study, part of the A-TRAIN initiative, aims to analyze blood-based genomic profiles of affected patients, contributing to personalized treatment development. Nasopharyngeal carcinoma has significant incidence rates in Southeast Asia, representing a critical area for new therapeutic strategies. The research involves up to 96 patients using Illumina's TruSight Oncology 500 ctDNA, highlighting regional collaboration for cancer treatment advancements.
Illumina, Inc. (NASDAQ: ILMN) will release its fourth quarter and full year 2021 financial results on February 10, 2022, after market close. The company's President and CEO, Francis deSouza, along with CFO Sam Samad, will host a conference call at 2:00 PM PT to discuss the results. Investors can access this call via Illumina's website or by dialing in. A replay will be available for 30 days post-event. Illumina focuses on enhancing health through genomic innovation and is a leader in DNA sequencing technologies.
Illumina (NASDAQ: ILMN) has announced a multi-year agreement with Nashville Biosciences, a subsidiary of Vanderbilt University Medical Center, to enhance drug development through large-scale genomics. This collaboration will utilize Illumina's next-generation sequencing technology to analyze data from VUMC's extensive biobank, which includes around 250,000 de-identified DNA samples. The initiative aims to identify disease targets, accelerate therapy development, and potentially lower costs, ultimately advancing personalized medicine efforts.
Illumina (NASDAQ: ILMN) has announced a multi-year partnership with Agendia to co-develop in vitro diagnostic tests for oncology, specifically targeting breast cancer. This collaboration aims to enhance the use of next-generation sequencing for decentralized testing. Agendia's MammaPrint test, which predicts breast cancer recurrence risk and is FDA-cleared, will be the first decentralized NGS-based test of its kind. The partnership seeks to leverage both companies' expertise to improve patient care and management globally.
Illumina has partnered with Boehringer Ingelheim to develop companion diagnostics for its oncology programs aimed at enhancing precision medicine for advanced cancer patients. The collaboration will fast-track therapy selection by adding companion diagnostic claims to Illumina's TruSight Oncology 500 assay. This initiative emphasizes the use of comprehensive genomic profiling to identify patients suited for novel therapies. Joydeep Goswami from Illumina expressed enthusiasm over the long-term partnership, highlighting its potential in unlocking new biomarkers critical for cancer treatment.
Illumina (NASDAQ: ILMN) reported a strong financial performance for 2021, with fourth-quarter revenue at approximately $1.190 billion (+25% YoY) and a full-year revenue of $4.517 billion (+39% YoY). The company anticipates 2022 revenue of $5.15-$5.24 billion, reflecting a growth of 14-16%. CEO Francis deSouza emphasized new partnerships in oncology and advancements in genomic technologies, including early cancer detection tests and innovative sequencing methods. These initiatives aim to enhance healthcare and drive further market penetration.
FAQ
What is the current stock price of Illumina (ILMN)?
What is the market cap of Illumina (ILMN)?
What does Illumina, Inc. specialize in?
What are Illumina's main revenue sources?
How is Illumina contributing to cancer research?
What are some recent achievements of Illumina?
What is the role of GRAIL in Illumina's operations?
How is Illumina expanding genomic literacy?
Where can one find Illumina's latest news and updates?
What types of genomic analysis does Illumina technology support?
What educational programs does Illumina offer?
How is Illumina addressing the global cancer burden?
